Dexcom CFO sells 3,638 shares at $83.27

Dexcom’s CFO sold 3,638 shares under a pre-arranged Rule 10b5-1 plan and continues to hold 146,828 shares including unvested RSUs.

Available on EDGAR 09/14/2026 - 04:03 PM EDT Accepted by SEC EDGAR 09/14/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

DEXCOM INC (DXCM) reported that EVP and Chief Financial Officer Jereme M. Sylvain sold 3,638 shares of common stock on September 10, 2026 at $83.27 per share in an open-market transaction. The sale was made under a Rule 10b5-1 trading plan adopted on June 10, 2026, and he now holds 146,828 shares directly, including 87,094 unvested restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 3,638 shares

Net Sell 1 txn

Insider Sylvain Jereme M

Role EVP, Chief Financal Officer

Sold 3,638 shs ($303K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	3,638	$83.27	$303K

Holdings After Transaction: Common Stock — 146,828 shares (Direct)

Footnotes (2)

1. F1. On June 10, 2026, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.
2. F2. Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 76 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.

Key Figures

Shares sold: 3,638 shares Sale price per share: $83.27 per share Shares held after transaction: 146,828 shares +4 more

7 metrics

Shares sold 3,638 shares Common stock sale by Dexcom CFO on September 10, 2026

Sale price per share $83.27 per share Price for the 3,638 Dexcom shares sold on September 10, 2026

Shares held after transaction 146,828 shares Direct Dexcom common stock holdings by CFO after the sale

Unvested restricted stock units 87,094 RSUs Unvested RSUs included in post-transaction share holdings

RSUs granted March 8, 2026 48,774 RSUs Portion of unvested RSUs vesting through March 8, 2029

Employee Stock Purchase Plan shares 76 shares Additional shares acquired under the 2015 Employee Stock Purchase Plan

Rule 10b5-1 plan adoption date June 10, 2026 Date Mr. Sylvain adopted the trading plan used for this sale

Key Terms

Rule 10b5-1 Plan, restricted stock units, Amended and Restated 2015 Employee Stock Purchase Plan, open market or private transaction

4 terms

Rule 10b5-1 Plan regulatory

"Mr. Sylvain adopted a 10b5-1 Plan on June 10, 2026"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock units financial

"Included in this number are 87,094 unvested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended and Restated 2015 Employee Stock Purchase Plan financial

"76 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan"

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dexcom (DXCM) disclose for CFO Jereme M. Sylvain?

Dexcom disclosed that CFO Jereme M. Sylvain sold 3,638 shares of common stock on September 10, 2026 at $83.27 per share. The filing characterizes this as a sale in an open market or private transaction under a Rule 10b5-1 trading plan.

Was the DXCM CFO’s September 2026 stock sale made under a Rule 10b5-1 plan?

Yes. The footnotes state that Mr. Sylvain adopted a Rule 10b5-1 Plan on June 10, 2026 and that the shares sold on September 10, 2026 were disposed of pursuant to this 10b5-1 Plan, allowing the orderly disposition of his shares.

How many Dexcom (DXCM) shares does the CFO hold after the reported sale?

After the September 10, 2026 sale, Mr. Sylvain holds 146,828 Dexcom common shares directly. A filing footnote explains that this figure includes 87,094 unvested restricted stock units and 76 additional shares acquired under Dexcom’s Amended and Restated 2015 Employee Stock Purchase Plan.

What unvested RSUs are included in the Dexcom (DXCM) CFO’s reported holdings?

The filing states that Mr. Sylvain’s holdings include 87,094 unvested restricted stock units: 48,774 granted March 8, 2026 vesting through March 8, 2029; 23,937 granted March 8, 2025 vesting through March 8, 2028; 5,699 granted March 8, 2025 vesting through March 8, 2027; and 8,684 granted March 8, 2024 vesting through March 8, 2027.

What role does Jereme M. Sylvain hold at Dexcom (DXCM) in this Form 4?

In this Form 4, Jereme M. Sylvain is identified as Executive Vice President and Chief Financial Officer of Dexcom. He is not listed as a director or ten percent owner in the reporting persons section of the filing, but as an officer with that specific title.

How many Dexcom (DXCM) shares did the CFO sell according to this Form 4?

The Form 4 reports that Mr. Sylvain sold 3,638 shares of Dexcom common stock on September 10, 2026 at a price of $83.27 per share. The transaction is classified as a sale of non-derivative common stock with direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sylvain Jereme M

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		S		3,638(1)	D	$83.27	146,828(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On June 10, 2026, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.

2. Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 76 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.

Remarks:

	/s/ Jereme M. Sylvain	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)